Engineered adult-like human heart tissue
A cardiac organoid containing 3-D matter of adult human heart tissue.
1. An engineered three-dimensional micro-tissue comprising a cell-hydrogel construct comprising electromechanically conditioned cardiomyocytes and fibroblasts encapsulated in a hydrogel wherein the electromechanically conditioned cardiomyocytes are mature cardiomyocytes including sarcomeres and a network of T-tubules, and wherein the electromechanical conditioning comprises subjecting the cell-hydrogel construct to electrical stimulation that increases in intensity over a time period, wherein the electrical stimulation results in the mature cardiomyocytes including sarcomeres and the network of T-tubules.
2. The engineered three-dimensional micro-tissue of claim 1 , wherein the engineered three-dimensional micro-tissue further comprises mitochondria or sarcoplasmic reticulum.
3. The engineered three-dimensional micro-tissue of claim 1 , wherein the sarcomeres comprise A- and I bands, and M- and Z-lines.
4. The engineered three-dimensional micro-tissue of claim 1 , wherein the network of T-tubules are disposed in at least longitudinal orientation or axial orientation.
5. The engineered three-dimensional micro-tissue of claim 1 , wherein the electromechanical stimulation comprises subjecting the engineered tissue to tension.
6. The engineered three-dimensional micro-tissue of claim 1 , wherein the engineered three-dimensional micro-tissue exhibits a positive force-frequency relationship.
7. The engineered three-dimensional micro-tissue of claim 6 , wherein the positive force-frequency relationship comprises a force of about 1 to about 2 mN/mm2 at a frequency of about 0 to about 6 Hz.
8. The engineered three-dimensional micro-tissue of claim 1 , wherein the electromechanical stimulation comprises a frequency that increases gradually from 2 Hz at the end of week 1 to 6 Hz over a 2-week time period, and at 6 Hz for one more week.
9. A method for producing mature engineered three-dimensional micro-tissue, comprising:
(a) encapsulating cardiomyocytes in a hydrogel; and
(b) conditioning the encapsulated cardiomyocytes of step (a) by exposing them to increasing intensities of electromechanical stimuli over a time period to yield a mature engineered three-dimensional micro-tissue that includes sarcomeres and a network of T-tubules.
10. The method of claim 9 , wherein the cardiomyocytes are derived by inducing stem cells.
11. The method of claim 9 , wherein the cardiomyocytes are derived from stem cells selected from the group consisting of embryonic stem cells, fetal stem cells, somatic stem cells, totipotent stem cells, pluripotent stem cells, multipotent stem cells, oligopotent stem cells, or unipotent cells.
12. A method for measuring the effect of a test agent on contractility of the engineered three-dimensional micro-tissue of claim 1 , comprising:
(a) measuring a first contractile force exerted by the micro-tissue prior to treatment with the test agent;
(b) measuring a second contractile force exerted by the micro-tissue after treatment with the test agent; and
(c) determining that the test agent affects contractility of the micro-tissue when the second contractile force is increased or decreased relative to the first contractile force.
13. A method for measuring the effect of a test agent on calcium homeostasis of the engineered three-dimensional micro-tissue of claim 1 , comprising:
(a) measuring a first calcium transients signal generated by the micro-tissue prior to treatment with the test agent, wherein the micro-tissue comprises a Ca 2+ -specific tracer or label;
(b) measuring a second calcium transients signal generated by the micro-tissue after treatment with the test agent; and
(c) determining that the test agent affects calcium homeostasis in the micro-tissue when the second calcium transients signal is increased or decreased relative to the first calcium transients signal.
14. The method of claim 13 , wherein the Ca 2+ -specific tracer or label is a Ca 2+ -specific fluorescent dye.